Cita APA

Voss, M. H., Gordon, M. S., Mita, M., Rini, B., Makker, V., & Macarulla Mercadé, T. (2020). Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.

Citación estilo Chicago

Voss, Martin H., Michael S. Gordon, Monica Mita, Brian Rini, Vicky Makker, y Teresa Macarulla Mercadé. Phase 1 Study of MTORC1/2 Inhibitor Sapanisertib (TAK-228) in Advanced Solid Tumours, With an Expansion Phase in Renal, Endometrial or Bladder Cancer. 2020.

Cita MLA

Voss, Martin H., et al. Phase 1 Study of MTORC1/2 Inhibitor Sapanisertib (TAK-228) in Advanced Solid Tumours, With an Expansion Phase in Renal, Endometrial or Bladder Cancer. 2020.